北米眼科市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2023 –2030 |
 市場規模（基準年） |
USD 20,704.35 Million |
 Market Size (Forecast Year) |
USD 34,946.97 Million |
 CAGR |
% |
| 主要市場プレーヤー |
>北米眼科市場、製品別（デバイス、薬剤、その他）、疾患別（緑内障、白内障、加齢性黄斑変性、炎症性疾患、屈折異常、その他）、処方モード別（ジェネリック、ブランド）、薬剤タイプ別（処方薬、市販薬）、投与経路別（経口、外用、注射、局所点眼薬、その他）、エンドユーザー別（病院、診療所、在宅医療、その他）、流通チャネル別（直接入札、小売販売、その他） - 2030年までの業界動向と予測。
北米眼科市場の分析と規模
眼科市場の成長を牽引する主な要因の 1 つは、眼科疾患および眼痛の罹患率の上昇です。いくつかの製薬企業がより良い治療法の選択のために行っている継続的な臨床試験研究と、特定の毒素や環境の変化への曝露により、眼科製品の出現が増加し、市場の拡大につながります。市場は、不衛生で座りがちなライフスタイルの増加と外傷の増加にも影響されています。ただし、眼科手術と治療に関連する高コストとリスク、特に発展途上国における国民の健康保険の欠如、眼科薬の製造と処方の長期化は、予測期間中の北米眼科市場の抑制要因として機能します。
北米の眼科市場は、2023年から2030年の予測期間に市場が成長すると予想されています。データブリッジマーケットリサーチは、市場は2023年から2030年の予測期間に6.8％のCAGRで成長し、2022年の207億435万米ドルから2030年までに349億4697万米ドルに達すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (2015～2020年にカスタマイズ可能) |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
製品タイプ（デバイス、医薬品、その他）、疾患（緑内障、白内障、加齢性黄斑変性、炎症性疾患、屈折異常、その他）、処方モード（ジェネリックおよびブランド）、医薬品タイプ（処方薬、市販薬（OTC）、投与経路（経口、外用、注射、局所点眼薬、その他）、エンドユーザー（病院、診療所、在宅医療、その他）、流通チャネル（直接入札、小売販売、その他） |
|
対象国 |
米国、カナダ、メキシコ。 |
|
対象となる市場プレーヤー |
Alcon, Regeneron Pharmaceuticals Inc., Johnson & Johnson, Inc., Reichert, Inc., Novartis AG, Bausch & Lomb Incorporated, HOYA Corporation., The Cooper Companies Inc., Santen Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Carl Zeiss Meditec AG, AbbVie Inc., EssilorLuxottica, NIDEK CO., LTD., TOPCON CORPORATION, Glaukos Corporation., STAAR SURGICAL, Metall Zug AG, Sun Pharmaceutical Industries Ltd., Lumenis Be Ltd., Pfizer Inc., and Ziemer Ophthalmic Systems AG, among others. |
Market Definition
Ophthalmology is a branch of medicine that deals with the anatomy, physiology, treatment and surgery of the visual pathways of the eye, including surrounding areas and the visual aspects of the brain. Ophthalmic devices are medical equipment designed for surgery, diagnosis, and vision correction. The devices gained increased importance and adoption due to the high prevalence of several ophthalmic diseases, such as glaucoma, cataract, and other vision-related issues. Ophthalmic drugs are medications that are specially designed and administered for the treatment of various eye-related disorders, including color blindness, diabetic macular edema, cytomegalovirus (CMV), and age-related macular degeneration (AMD).
Ophthalmology Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising prevalence of ophthalmic disorders & ocular pains
Ophthalmic disorders are the vital cause of major ocular and orbital pains in the eye. Ocular pain occurs over the surface of the eyes along with symptoms such as scratching, burning, or itching sensation. This may be due to multiple reasons, including irritation from foreign objects, infection or trauma. Eyelashes or pieces of dirt, smoke, dust or some harsh eye cosmetics are the common causes leading to ocular pain, redness, and watery eyes.
The prevalence of ocular pain keeps showing a surge in growth as chemical industries and pollution around the world are growing. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface. Style and blepharitis lead to severe ocular pain as they cause eye and oil glands to be more sensitive around the area. The affirmative factor states that this is the major driver for the North America ophthalmology market.
- Rise in traumatic injuries
Traumatic head injury is one of the causes of such disorders as optic nerve disorders. A traumatic injury is a physical injury that occurs suddenly with a certain degree of severity. Trauma can be caused by a variety of external injuries. The most common causes of traumatic injury include road accidents, sports injuries, and violence, among others which can lead to some serious eye disorders as well. The prevalence of such traumatic injuries is highly seen worldwide.
Hence, such traumatic injuries lead to optic nerve disorders, which are affecting the population in these years and it is increasing with the rising population. Therefore, a rise in traumatic injuries is expected to drive market growth.
Opportunities
-
Rise in healthcare expenditure and disposable income
Healthcare expenditure and its growth rate over time are inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization of the health system.
Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking initiatives by virtue of accelerating healthcare expenditure.
Growing healthcare expenditure is also beneficial for further economic growth and healthcare sector growth. It is primarily fruitful as it significantly affects the development of better and more advanced medical products in the market. Therefore, the surge in healthcare expenditure may act as a great opportunity for market growth.
-
Rising awareness to prevent the burden of eye diseases
Significant advancements in the prevention of visual impairment have been made to battle visible diseases by various organizations such as World Health Organization (WHO) and its Member States, UN agencies, Non-Governmental Organizations (NGOs) and the private sector. Therefore, the second Thursday of October is World Sight Day (WSD), an annual awareness day to create North America attention on blindness and vision impairment.
Thus, the programs and initiatives to reduce the burden of eye diseases are expected to create opportunities for the growth of the North America ophthalmology market in the forecast period.
Restraints/Challenges
- High cost & risks associated with eye surgery & treatment
The cost of the various disorders treatment plays a major role in the market. The optic nerve disorders treatments are highly sophisticated, as the prevalence of such disorders is increasing; hence the need for such products has eventually raised, thereby raising the treatment cost, which can hinder the market growth in the coming years.
There are various methods for the treatment of optic neuritis disorder. Some of them are patients can take various medicines such as corticosteroids like methylprednisolone, prednisone, immunoglobulin, vitamin B12 shots and various other surgeries. With these, there are some of the risks associated with it.
Therefore, for some of the population around the country, it is difficult for them to undergo such treatments due to the high cost. Hence, the high cost associated with ophthalmic disorders treatment is expected to restrain market growth.
- Lack of skilled professionals
The number of ophthalmologists in both emerging and industrialized countries is minor. However, projections are a little higher for developing countries. The number of ophthalmologists is cumulative but not as fast as the population of elderly patients aged 60 years or older who need to be amplified ophthalmologic care. In most countries, the problem is that demographic changes do not match up with professional development. It is required to train eye care teams to meet the current number of ophthalmologists worldwide. The increased need for ophthalmologists globally also reflects an increase in the cases of diabetes. Diabetic patients should get their eyes inspected every year. The increasing demand for ophthalmologists is directly proportional to the growing geriatric population since eye care is an integral part of healthcare. The access to care gaps can be met by combining factors, including more efficient practice structures, processes and appropriate use of technology.
Post-COVID-19 Impact on the Ophthalmology market
The COVID-19 pandemic had a great impact on the ophthalmology and surgical industries. Trade groups in the ophthalmic and vision products sector claim that the North America supply chain for operating, diagnostic and vision care products has been significantly damaged, impacting end-user consumption of the ophthalmology market. Sales of vision care products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get operated after the lockdown scenario. The situation needs to be taken into consideration, and emergency operations need to be operated. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and vision care instruments.
Recent Developments
- In October 2022, Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. This development helps the organization in developing its brand image in the ophthalmology market, among others
- In May 2022, Reichert, Inc. has launched its redesigned refractometers & analytical instruments website with a vastly improved user experience
North America Ophthalmology Market Scope
The North America ophthalmology market is segmented into products, disease, prescription mode, drug type, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Products
- Device
- Drugs
- Others
製品に基づいて、眼科市場はデバイス、医薬品、その他に分類されます。
病気
- 緑内障
- 白内障
- 加齢黄斑変性症
- 炎症性疾患
- 屈折異常
- その他
眼科市場は、疾患に基づいて、緑内障、白内障、加齢黄斑変性、炎症性疾患、屈折異常などに分類されます。
処方モード
- ジェネリック
- ブランド
処方モードに基づいて、眼科市場はジェネリックとブランドに分類されます。
薬剤の種類
- 処方箋
- 店頭販売（OTC）
薬剤の種類に基づいて、眼科市場は処方薬と市販薬（OTC）に分類されます。
投与経路
- オーラル
- 話題
- 注射剤
- 地元の眼科
- その他
投与経路に基づいて、眼科市場は経口、局所、注射、局所点眼薬、その他に分類されます。
エンドユーザー
- 病院
- クリニック
- 在宅医療
- その他
エンドユーザーに基づいて、眼科市場は病院、診療所、在宅医療、その他に分類されます。
流通チャネル
- 直接入札
- 小売販売
- その他
流通チャネルに基づいて、眼科市場は直接入札、小売販売、その他に分類されます。
眼科市場の地域分析/洞察
北米のガスケット市場は、製品、疾患、処方モード、薬剤の種類、投与経路、エンドユーザー、流通チャネルに基づいて分類されています。
北米のガスケット市場が存在する国は、米国、カナダ、メキシコです。
米国は眼科製品の需要増加により優勢を占めており、業界における研究開発活動の増加も予測期間中に市場を牽引すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。データポイントの下流および上流のバリューチェーン分析、技術動向、ポーターの 5 つの力の分析、およびケーススタディは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、北米ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、国内関税の影響、貿易ルートも考慮されます。
競争環境と北米眼科市場シェア分析
眼科市場の競争状況は、競合他社による詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、北米でのプレゼンス、生産拠点と施設、生産能力、会社の長所と短所、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、北米の眼科市場への会社の焦点にのみ関連しています。
この市場で活動している主要企業としては、アルコン、リジェネロン・ファーマシューティカルズ社、ジョンソン・エンド・ジョンソン社、ライヒェルト社、ノバルティス社、ボシュロム社、HOYA株式会社、クーパー・カンパニーズ社、参天製薬株式会社、F・ホフマン・ラ・ロシュ社、カールツァイスメディテック社、アッヴィ社、エシロールルックスオティカ社、ニデック社、トプコン社、グラウコス社、スターサージカル社、メタル・ツーク社、サン・ファーマシューティカル・インダストリーズ社、ルメニス・ビー社、ファイザー社、ジーマー・オフタルミック・システムズ社などが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA OPHTHALMOLOGY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 NORTH AMERICA OPHTHALMOLOGY MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 STRATEGIC INITIATIVES
7 NORTH AMERICA OPHTHALMOLOGY MARKET, REGULATION
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING PREVALENCE OF OPHTHALMIC DISORDERS & OCULAR PAINS
8.1.2 INCREASING UNHYGIENIC & SEDENTARY LIFESTYLE
8.1.3 RISE IN TRAUMATIC INJURIES
8.1.4 RISE IN THE GERIATRIC POPULATION
8.2 RESTRAINTS
8.2.1 HIGH COST & RISKS ASSOCIATED WITH EYE SURGERY & TREATMENT
8.2.2 LACK OF HEALTH INSURANCE AMONGST THE POPULATION, ESPECIALLY WITHIN THE DEVELOPING COUNTRIES
8.2.3 SIDE EFFECTS ASSOCIATED WITH TREATMENT DRUGS
8.3 OPPORTUNITIES
8.3.1 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
8.3.3 RISING AWARENESS TO PREVENT THE BURDEN OF EYE DISEASES
8.4 CHALLENGE
8.4.1 LACK OF SKILLED PROFESSIONALS
8.4.2 STRINGENT RULES & REGULATIONS FOR PRODUCT APPROVAL
9 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRODUCTS
9.1 OVERVIEW
9.2 DEVICE
9.2.1 SURGICAL DEVICE
9.2.1.1 CATARACT SURGICAL DEVICES
9.2.1.2 OPHTHALMIC VISCOELASTIC DEVICES
9.2.1.2.1 PHACOEMULSIFICATION DEVICES
9.2.1.2.2 CATARACT SURGICAL LASERS
9.2.1.2.3 IOL INJECTORS
9.2.1.3 VITREORETINAL SURGICAL DEVICES
9.2.1.3.1 VITREORETINAL PACKS
9.2.1.3.2 VITRECTOMY MACHINES
9.2.1.3.3 VITRECTOMY PROBES
9.2.1.3.4 PHOTOCOAGULATION LASERS
9.2.1.3.5 ILLUMINATION DEVICES
9.2.1.4 REFRACTIVE SURGICAL DEVICES
9.2.1.4.1 FEMTOSECOND LASERS
9.2.1.4.2 EXCIMER LASERS
9.2.1.4.3 OTHER REFRACTIVE SURGICAL LASERS
9.2.1.5 GLAUCOMA SURGICAL DEVICES
9.2.1.5.1 GLAUCOMA DRAINAGE DEVICES
9.2.1.5.2 GLAUCOMA LASER SYSTEMS
9.2.1.5.3 MICRO INVASIVE GLAUCOMA SURGERY DEVICES
9.2.2 DIAGNOSTIC DEVICE
9.2.2.1 AUTOREFRACTORS & KERATOMETERS
9.2.2.2 TONOMETER
9.2.2.3 PHOROPTERS
9.2.2.4 RETINOSCOPES
9.2.2.5 OPHTHALMOSCOPES
9.2.2.6 PERIMETERS/VISUAL FIELD ANALYZERS
9.2.2.7 OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
9.2.2.7.1 A- SCAN IMAGING SYSTEM
9.2.2.7.2 B-SCAN IMAGING SYSTEM
9.2.2.7.3 PACHYMETERS
9.2.2.7.4 ULTRASOUND BIOMICROSCOPES
9.2.2.8 LENSMETERS
9.2.2.9 CORNEAL TOPOGRAPHY SYSTEMS
9.2.2.10 OPTICAL COHERENCE TOMOGRAPHY SCANNERS
9.2.2.11 FUNDUS CAMERAS
9.2.2.12 OPTICAL BIOMETRY SYSTEMS
9.2.2.13 SPECULAR MICROSCOPES
9.2.2.14 WAVEFRONT ABERROMETERS
9.2.2.15 CHART PROJECTORS
9.2.2.16 SLIT LAMPS
9.2.3 OPHTHALMIC SURGICAL ACCESSORIES
9.2.3.1 SURGICAL INSTRUMENTS & KITS
9.2.3.2 OPHTHALMIC FORCEPS
9.2.3.3 OPHTHALMIC SPATULA
9.2.3.4 OPHTHALMIC TIPS AND HANDLES
9.2.3.5 OPHTHALMIC CANNULAS
9.2.3.6 OPHTHALMIC SCISSORS
9.2.3.7 OTHERS SURGICAL ACCESSORIES
9.2.4 OPHTHALMIC MICROSCOPES
9.3 DRUGS
9.3.1 ANTI-INFLAMMATION DRUGS
9.3.1.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.1.2 STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.2 ALLERGIC CONJUNCTIVITIS
9.3.3 DRY EYE DRUGS
9.3.4 RETINAL DISORDER DRUGS
9.3.5 ANTI-GLAUCOMA DRUGS
9.3.5.1 MIOTICS
9.3.5.1.1 PILOCARPINE
9.3.5.1.2 ESERINE
9.3.5.2 BETA ADRENERGIC ANTAGONISTS
9.3.5.2.1 TIMOLAL MALEATE
9.3.5.2.2 BETAXOLOL
9.3.5.3 PROSTAGLANDIN ANALOGS
9.3.5.3.1 LATANOPROST
9.3.5.3.2 BIMATOPROST
9.3.5.3.3 TRAVOPROST
9.3.5.3.4 TAFLUPROST
9.3.5.3.5 LATANOPROSTENE
9.3.5.4 ALPHA ADRENERGIC AGONISTS
9.3.5.4.1 EPINEPHRINE
9.3.5.4.2 DEPIVEPRINE
9.3.5.5 ANTI-VEGF DRUGS
9.3.5.5.1 RANIBIZUMAB
9.3.5.5.2 BEVACIZUMAB
9.3.6 OTHERS
9.4 OTHERS
9.4.1 VISION CARE PRODUCTS
9.4.1.1 SPECTACLES
9.4.1.2 CONTACT LENSES
9.4.1.2.1 SOFT CONTACT LENSES
9.4.1.2.2 HYBRID CONTACT LENSES
9.4.1.2.3 RIGID GAS PERMEABLE LENSES
9.4.2 OTHERS
10 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISEASES
10.1 OVERVIEW
10.2 INFLAMMATORY DISEASES
10.3 CATARACT
10.4 REFRACTIVE DISORDERS
10.5 GLAUCOMA
10.6 AGE-RELATED MACULAR DEGENERATION
10.7 OTHERS
11 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE
11.1 OVERVIEW
11.2 BRANDED
11.3 GENERIC
12 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 NORTH AMERICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 EYE DROPS
13.2.2 EYE SOLUTION
13.2.3 CREAM & OINTMENTS
13.2.4 GEL
13.2.5 OTHERS
13.3 ORAL
13.3.1 TABLET
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 LOCAL OCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 INTRAVITREAL
13.4.3 RETROBULBAR
13.4.4 INTRACAMERAL
13.5 INJECTABLE
13.5.1 INTRAMUSCULAR
13.5.2 INTRAVENOUS
13.5.3 OTHERS
13.6 OTHERS
14 NORTH AMERICA OPHTHALMOLOGY MARKET, BY END USER
14.1 OVERVIEW
14.2 CLINICS
14.3 HOSPITALS
14.4 HOMECARE SETTINGS
14.5 OTHERS
15 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 RETAIL SHOPS
15.2.2 HOSPITAL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
15.4 OTHERS
16 NORTH AMERICA OPHTHALMOLOGY MARKET, BY GEOGRAPHY
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA OPHTHALMOLOGY MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 ALCON
19.1.1 COMPANY SNAPSHOT
19.1.2 RECENT FINANCIALS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 REGENERON PHARMACEUTICALS INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 RECENT FINANCIALS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 JOHNSON & JOHNSON SERVICES, INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 RECENT FINANCIALS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 REICHERT, INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENT
19.5 NOVARTIS AG
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ABBVIE INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 RECENT FINANCIALS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BAUSCH & LOMB INCORPORATED
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 CARL ZEISS MEDITEC AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 ESSILORLUXOTTICA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMEN
19.1 F. HOFFMANN- LA ROCHE LTD
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 GLAUKOS
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 HEIDELBERG ENGINEERING GMBH
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 HOYA CORPORATION
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 LUMENIS BE LTD.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 METALL ZUG AG
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 NEOVISION
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 NIDEK CO., LTD.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 SANTEN PHARMACEUTICAL CO., LTD.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT FINANCIALS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 RECENT FINANCIALS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 STAAR SURGICAL
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 THE COOPER COMPANIES INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
19.23 TOPCON CORPORATION
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 VISIONIX
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 ZIEMER OPHTHALMIC SYSTEMS AG
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表のリスト
TABLE 1 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA DEVICE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA DRUGS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA ANTI INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA ANTI GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION))
TABLE 25 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISEASES 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA INFLAMMATORY DISEASES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA CATARACT IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA REFRACTIVE DISORDERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA GLAUCOMA IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA BRANDED IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA GENERIC IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DRUG TYPE 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA OVER THE COUNTER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA PRESCRIPTION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA TOPICAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA ORAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA CLINICS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA HOSPITALS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA HOME HEALTHCARE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA DIRECT TENDER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA OPHTHALMOLOGY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 81 NORTH AMERICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 82 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 NORTH AMERICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 84 NORTH AMERICA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 85 NORTH AMERICA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 NORTH AMERICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 NORTH AMERICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 88 NORTH AMERICA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 NORTH AMERICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 90 NORTH AMERICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 91 U.S. OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 92 U.S. DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 93 U.S. SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 94 U.S. OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 95 U.S. VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 96 U.S. REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 97 U.S. GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 98 U.S. DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 99 U.S. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 100 U.S. OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 101 U.S. DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 102 U.S. ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 103 U.S. ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 U.S. MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 U.S. BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 U.S. PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 U.S. ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 U.S. ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 U.S. OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 U.S. VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 U.S. CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 U.S. OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 113 U.S. OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 114 U.S. OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 115 U.S. OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 U.S. TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 U.S. ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 118 U.S. LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 119 U.S. INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 120 U.S. OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 121 U.S. OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 122 U.S. RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 123 CANADA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 124 CANADA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 125 CANADA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 126 CANADA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 127 CANADA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 128 CANADA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 129 CANADA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 130 CANADA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 131 CANADA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 132 CANADA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 133 CANADA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 134 CANADA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 135 CANADA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 136 CANADA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 137 CANADA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 138 CANADA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 139 CANADA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 140 CANADA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 141 CANADA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 142 CANADA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 143 CANADA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 144 CANADA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 145 CANADA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 146 CANADA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 147 CANADA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 148 CANADA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 149 CANADA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 150 CANADA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 151 CANADA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 152 CANADA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 153 CANADA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 154 CANADA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 155 MEXICO OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 MEXICO DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 MEXICO SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 MEXICO OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 MEXICO VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 MEXICO REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 MEXICO GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 MEXICO DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 163 MEXICO OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 164 MEXICO OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 165 MEXICO DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 166 MEXICO ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 167 MEXICO ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 168 MEXICO MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 169 MEXICO BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 170 MEXICO PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 171 MEXICO ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 172 MEXICO ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 173 MEXICO OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 174 MEXICO VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 175 MEXICO CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 176 MEXICO OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 177 MEXICO OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 178 MEXICO OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 MEXICO OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 180 MEXICO TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 181 MEXICO ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 182 MEXICO LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 183 MEXICO INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 184 MEXICO OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 185 MEXICO OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 MEXICO RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA OPHTHALMOLOGY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA OPHTHALMOLOGY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA OPHTHALMOLOGY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA OPHTHALMOLOGY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA OPHTHALMOLOGY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA OPHTHALMOLOGY MARKET: DBMR POSITION GRID
FIGURE 8 NORTH AMERICA OPHTHALMOLOGY MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA OPHTHALMOLOGY MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF OPHTHALMIC DISORDERS& INCREASING GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE NORTH AMERICA OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 12 THE DEVICE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA OPHTHALMOLOGY MARKET
FIGURE 14 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRODUCTS, 2022
FIGURE 15 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRODUCTS, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRODUCTS, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 18 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISEASES, 2022
FIGURE 19 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISEASES, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISEASES, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 22 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE ,2022
FIGURE 23 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DRUG TYPE ,2022
FIGURE 27 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 31 NORTH AMERICA OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA OPHTHALMOLOGY MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 34 NORTH AMERICA OPHTHALMOLOGY MARKET: BY END USER, 2022
FIGURE 35 NORTH AMERICA OPHTHALMOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 NORTH AMERICA OPHTHALMOLOGY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 NORTH AMERICA OPHTHALMOLOGY MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 40 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 41 NORTH AMERICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 NORTH AMERICA OPHTHALMOLOGY MARKET: SNAPSHOT (2022)
FIGURE 43 NORTH AMERICA OPHTHALMOLOGY MARKET: BY COUNTRY (2022)
FIGURE 44 NORTH AMERICA OPHTHALMOLOGY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 45 NORTH AMERICA OPHTHALMOLOGY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 46 NORTH AMERICA OPHTHALMOLOGY MARKET: PRODUCTS (2023-2030)
FIGURE 47 NORTH AMERICA OPHTHALMOLOGY MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
